Atrazine [2-chloro-4-(ethylamino)-6-(isopropylamino)-s-triazine] is one of the most commonly used herbicides in the United States. Atrazine has been shown to suppress luteinizing hormone (LH) release and can lead to a prolongation of the estrous cycle in the rat. The objectives of this study were to examine the effects of atrazine on normal tonic release of LH and to elucidate the site of action of atrazine in the hypothalamic-pituitary-gonadal axis. Episodic release of gonadotropin-releasing hormone (GnRH) and the corresponding release of LH from the anterior pituitary gland are required for normal reproductive function. To determine if atrazine affects pulsatile LH release, ovariectomized adult female Wistar rats were administered atrazine (50, 100, or 200 mg/kg of body weight daily by gavage) or vehicle control for 4 days. On the final day of atrazine treatment, blood samples were obtained using an indwelling right atrial cannula. In the group receiving 200 mg/kg, there was a significant reduction in LH pulse frequency and a concomitant increase in pulse amplitude. To determine if the effects of atrazine on LH release were due to changes at the level of the pituitary, animals were passively immunized against endogenous GnRH, treated with atrazine, and challenged with a GnRH receptor agonist. Atrazine failed to alter pituitary sensitivity to the GnRH receptor agonist at any dose used. Taken together, these findings demonstrate that high doses of atrazine affect the GnRH pulse generator in the brain and not at the level of gonadotrophs in the pituitary.
INTRODUCTION
Atrazine [2-chloro-4-(ethylamino)-6-(isopropylamino)-s-triazine] is one of the most commonly used herbicides in the United States, with 57.4 million pounds applied in 2005 [1] . It is used primarily to control weeds in corn and sorghum fields before and after emergence. In plants, its principal mode of action is to inhibit the Hill reaction in photosynthesis [2] . In rats, atrazine and its primary metabolites have been shown to inhibit the preovulatory surge of luteinizing hormone (LH) and prolactin [3] [4] [5] [6] . In addition, atrazine treatment can delay the onset of puberty in both sexes [7, 8] and reduce basal testosterone levels [9] [10] [11] . These effects may also be mediated through an atrazine-induced suppression of LH release, as it is known that the onset of puberty is associated with an increasing nocturnal release of LH [12] [13] [14] [15] and that circhoral release of LH is associated with testosterone release from the testes [16, 17] .
To our knowledge, the site of action for the effects of atrazine on the hypothalamic-pituitary-gonadal axis has not been elucidated. In these studies, we tested the overall hypothesis that atrazine acts at the level of the brain to disrupt gonadotropin-releasing hormone (GnRH) release. In the absence of variations in pituitary sensitivity to GnRH, changes in LH secretion are directly coupled to alterations in GnRH release [18] [19] [20] . Using an indwelling intra-atrial cannula, we tested the hypothesis that atrazine would disrupt the pulsatile release of LH in the freely moving ovariectomized rat. To ensure that the effects observed were not a consequence of atrazine-dependent alterations in pituitary sensitivity to GnRH, some animals were passively immunized against GnRH to remove the endogenous signal, and pituitary sensitivity to the GnRH receptor agonist D-Ala-6 GnRH was examined following atrazine exposure.
MATERIALS AND METHODS

Animals
All animal surgical procedures and experimental protocols were approved by the Animal Care and Use Committee at Colorado State University and were performed in accord with National Institutes of Health and Association for Assessment and Accreditation of Laboratory Animal Care International guidelines. Young adult female Wistar rats (60-90 days old) were obtained from Charles Rivers (Wilmington, MA). Animals were single housed in the Colorado State University vivarium and were maintained on a 12D:12L schedule (lights on at 0700 h) with ad libitum access to food and water. Following time to acclimate to the vivarium, all animals were ovariectomized and were allowed 7-8 days to recover before additional procedures were performed.
Intra-Atrial Cannulation
To determine the level and pattern of LH secretion, we used a chronic indwelling cannulation procedure to discretely remove blood samples from freely moving rats in the animals' home cage. This procedure has been described in detail [21] and is a modification of that by Harms and Ojeda [22] and by Garner et al. [23] . Briefly, a cannula of Silastic tubing (0.037-in outer diameter and 0.020-in inner diameter) was inserted into the right atrium via the right jugular vein. The cannula was fixed to the pectoralis major muscle and was externalized at the back by tunneling under the skin and by allowing the end to hang free. The cannula was sealed with a piece of 23-gauge stainless steel. For blood sampling, a length of polyethylene-50 tubing was attached to the free end of the cannula, and 150-ll samples of blood were obtained at discrete intervals via the cannula during the sampling session. All blood samples were taken 10 or 11 days after ovariectomy, and treatments were counterbalanced to control for differences due to duration of time after ovariectomy. We previously used this method to sample blood from freely moving animals under nonstressful conditions as indicated by the absence of any significant increases in stress hormone (adrenocorticotropin) during sampling [24] .
Experiment 1: Effects of Atrazine on LH Pulse Frequency and Amplitude
The objective of this experiment was to determine if atrazine treatment alters LH secretory patterns in freely moving rats. Ovariectomized animals were administered atrazine in 1% carboxymethylcellulose sodium salt (CBC) (Sigma-Aldrich, Atlanta, GA) by gavage once daily for 4 consecutive days in the morning (50, 100, or 200 mg/kg of body weight [5-6 animals per group]). Control animals received CBC only. On the second day of atrazine treatment, intra-atrial cannulae were implanted. Three to four hours after the final dose of atrazine, blood was serially sampled via the intra-atrial cannula at 5-min intervals for 3 h. All plasma samples were saved for analysis of LH levels using radioimmunoassay. A total of 5.5 ml of whole blood was collected during the 3-h sampling session. To maintain hematocrit and electrolyte balance following repeated blood sampling, red blood cells were collected from each sample, resuspended in sterile saline, and reinfused into the same animal following each subsequent sample after the second sample was withdrawn, as previously described by Coquelin and Bronson [25] .
Experiment 2: Validation of Protocol for GnRH Immunoneutralization and Pituitary Response to GnRH Agonist
Animals were fitted with an indwelling intra-atrial cannula as already described. At the time of cannula placement, all animals were administered GnRH antiserum (300 lL) via cannula to block the actions of endogenous GnRH. The anti-GnRH serum was prepared against keyhole limpet hemocyanin-conjugated GnRH, which has previously been shown to effectively suppress GnRH action in the mouse and ewe [26, 27] . Two days after cannula placement, blood samples were obtained from individual animals at 10-min intervals for a 100-min period. Animals were sampled remotely while awake and in their home cage using polyethylene-50 tubing that was attached to the intra-atrial cannula on the day of sampling at least 1 h before the blood sampling session. After the third sample was collected, animals were treated with one of four doses of the GnRH receptor agonist D-Ala 6 -des-Gly-NH 2 10 -GnRH-ethylamide (D-Ala-6 GnRH) (0.01, 0.1, 1.0, or 10 ng [4-6 animals per treatment group]). D-Ala-6 GnRH is not bound by the GnRH antiserum and thus is free to bind to and activate the GnRH receptor [28] . Blood samples (150 ll) were removed from the indwelling cannula, and plasma was saved following centrifugation. Red blood cells were resuspended in sterile saline and were reinfused to the animal to maintain hematocrit and blood volume during the sampling procedure. All plasma samples were saved for analysis of LH levels by radioimmunoassay [29] .
Experiment 3: Effects of Atrazine on In Vivo Pituitary Response to GnRH Agonist
The objective of this experiment was to determine whether atrazine reduces pituitary sensitivity to a GnRH agonist. Ovariectomized rats were administered atrazine by gavage (once daily for 4 consecutive days in the morning [0, 50, 100, or 200 mg/kg] [4-6 animals per group]). On the second day of atrazine treatment, intra-atrial cannulae were implanted, and animals were treated with anti-GnRH serum via cannula. On the afternoon of the final day of atrazine treatment, blood was serially sampled via the intra-atrial cannula. Blood samples (150 ll) were obtained at 10-min intervals. After three samples were taken (30 min) to establish a stable baseline, a single bolus of D-Ala-6 GnRH (0.1 or 1.0 ng in saline vehicle) was administered via the catheter. Sampling was continued for an additional 90 min. In all cases, plasma was saved following centrifugation, and red blood cells were resuspended in sterile saline and reinfused to the animal to maintain hematocrit and blood volume during the sampling procedure. All plasma samples were saved for analysis of LH levels by radioimmunoassay.
Radioimmunoassay
Plasma levels of LH were measured using reagents provided by the National Hormone and Peptide Program (Torrance, CA). Rat LH-RP3 was used to create a standard curve. Tracer LH was iodinated using the chloramine-T method by the Colorado State University peptide assay core. The assay sensitivity averaged 0.12 ng/ml (n ¼ 4); intraassay and interassay coefficients of variation for this assay were 6.05% and 7.48%, respectively.
Data Analysis
Data for LH were analyzed for the presence of pulses using a method similar to that described by Gallo [30] . A pulse was defined as a group of at least three data points whose coefficients of variation of the ascending and descending limbs are more than two times the coefficient of variation of the assay at the mean level. The pulse amplitude was calculated by subtracting the preceding nadir value from the greatest pulse value. The pulse period was determined by dividing the blood sampling period by the number of identified pulses. The LH pulse frequency was then analyzed using Friedman two-way ANOVA, and differences in LH pulse amplitude and concentrations were analyzed by twoway ANOVA for repeated measures. When significant differences were observed, Dunnett post hoc test was used to determine which groups differed from blank controls. The level of statistical significance was set at P 0.05.
RESULTS
Experiment 1: Effects of Atrazine on LH Pulse Frequency and Amplitude
There was no significant difference in LH pulse period between the groups receiving 50 vs. 100 mg/kg per day (mean 6 SEM pulse period, 31.6 6 2.8 vs. 28.9 6 1.1 min) compared with the mean pulse period of the control group (26.20 6 0.99 min) (Figs. 1, A and B, and 2A ). Animals treated with 200 mg/kg of atrazine had a significantly longer mean 6 SEM pulse period of 36.8 6 3.4 min (F (3,18) ¼ 3.87, P ¼ 0.023) (Figs. 1C and 2A) .
Atrazine treatment also affected the peak LH amplitude (Figs. 1 and 2B) . Control animals had a mean 6 SEM peak LH amplitude of 6.36 6 1.94 ng/ml. Animals treated with 50 vs. 100 mg/kg of atrazine showed no significant difference in the mean 6 SEM LH peak amplitude (6.69 6 1.82 vs. 6.3 6 2.05 ng/ml), whereas the animals treated with 200 mg/kg of atrazine had a significantly increased LH amplitude (14.79 6 2.82 ng/ ml; F (3,18) ¼ 3.54, P , .05) compared with the control group (Figs. 1C and 2B ).
Experiment 2: Validation of Protocol for GnRH Immunoneutralization and Pituitary Response to GnRH Agonist
Plasma LH levels were at or below the detection level of the assay in animals administered the GnRH antiserum, indicating that the effect of endogenous GnRH on the pituitary release of LH was effectively suppressed (Fig. 3) . The infusion of one of four doses (10, 100, 1000, or 10 000 pg) of the GnRH agonist D-Ala-6 GnRH resulted in dose-dependent increases in the mean plasma LH levels. However, there was a time component to the efficacy of the different doses of GnRH agonist. The lowest dose of D-Ala-6 GnRH (10 pg) failed to increase LH levels above baseline until 50 min after the agonist treatment (F (1, 8) The mean LH levels of the highest of dose of D-Ala-6 GnRH were significantly elevated above levels of animals treated with ATRAZINE INHIBITS LH WITHOUT ALTERING PITUITARY the lowest dose of 10 pg at the time points of 50, 60, 70, 90, and 100 min (P , 0.05). Similarly, the LH levels of animals administered 1 ng were significantly above those seen in the animals administered 10 pg at the time points of 70, 90, and 100 min (P , 0.05). At no time point were LH levels in animals treated with 100 pg of D-Ala-6 GnRH different from those of any other group (Fig. 3 ).
Experiment 3: Effects of Atrazine on In Vivo Pituitary Response to GnRH Agonist
Atrazine-treated animals (50, 100, or 200 mg/kg) that had been immunoneutralized with the anti-GnRH serum showed an LH response comparable to that observed in the control group when administered 100 pg or 1 ng of the GnRH agonist D-Ala-6 GnRH (F (1,3) ¼ 1.88, P ¼ 0.167 for 1 ng; and F (1,3) ¼ 0.312, P ¼ .813 for 100 pg) (Fig. 4) . As in experiment 1, both doses of D-Ala-6 GnRH (1 ng and 100 pg) caused an increase in the circulating concentration of LH (F (3, 11) ¼ 33.42, P , 0.0001; and F (3,11) ¼ 35.65, P , 0.0001; respectively). However, in no case was there a significant change in the levels of LH related to atrazine treatment. reproductive function [31] [32] [33] . Disruption of normal GnRH/ LH pulsatility leads to nonresponsive gonadotrophs and to loss of reproductive function [34] [35] [36] . In the present study, ovariectomized animals were treated for 4 days with atrazine. Doses of 50 and 100 mg/kg had no significant effect on LH pulses compared with each other or vs. control animals. Only the high dose of atrazine, 200 mg/kg, resulted in a reduction in pulse frequency and a corresponding increase in pulse period (time between pulses) compared with control animals (Figs. 1  and 2 ). Moreover, an increased pulse amplitude was identified in animals treated with 200 mg/kg per day. The increased amplitude is most likely due to the reduced frequency of GnRH pulses, which in itself can lead to increased LH pulse amplitude because of an inverse relationship between the two [37] . There were no significant differences identified in pulse duration in any of the groups. Given the close association between GnRH pulses and LH pulses, these findings suggest that atrazine works at the level of the brain to decrease GnRH release.
However, these results do not completely rule out the possibility that atrazine may also affect pituitary sensitivity to endogenous GnRH or other aspects of pituitary signal transduction pathways. Indeed, high concentrations of atrazine have been shown to be toxic to cultured pituitary cells [38] . In addition, the atrazine metabolite diaminochlorotriazine (DACT) has been found in pituitary cells of atrazine-treated animals [39] , and female rats treated with DACT have a slightly lower response to exogenous GnRH, suggesting a change in pituitary sensitivity to GnRH [4] .
Conversely, findings by Cooper et al. [3] indicate (in support of our results) that atrazine does not affect pituitary sensitivity to GnRH; in intact animals, atrazine failed to inhibit LH release in response to exogenous GnRH. In their experiment, there was no direct comparison with control animals, and animals were also likely receiving stimulation from endogenous GnRH, which could have interfered with interpretation of the results. Subsequently, this group showed that atrazine perfused over ex vivo pituitaries did not change the response to GnRH. However, if the effects seen in vivo are dependent on creation of atrazine metabolites produced by the presence of liver enzymes in vivo, then the same effects would not have been seen with the perfusion of atrazine alone [4, 40] .
A previous study [4] in our laboratory showed that atrazine caused a small reduction in LH levels in response to GnRH in estrogen-and progesterone-primed female rats. Unfortunately, this experiment again relied on the assumption that endogenous GnRH secretions from the animals would not affect LH levels. Therefore, any differences identified between atrazine-treated animals and controls may have been due to reduced pituitary response to the exogenous GnRH or due to the effect of atrazine on the endogenous release of GnRH.
To better address this issue, in the present studies we removed the endogenous GnRH input to the pituitary by using a passive immunoneutralization approach in ovariectomized animals. Similar to previous findings in sheep [27] and mouse [26] , infusion of this GnRH antiserum was an effective way to remove the endogenous GnRH signal in the rat. Levels of LH were at or below the detection level of the assay in samples obtained before the GnRH receptor agonist D-Ala-6 GnRH was administered, demonstrating a lack of GnRH input to the pituitary (Figs. 3 and 4) . A dose response to the D-Ala-6 GnRH infusion was evident in LH values of samples obtained within 20 min after the GnRH agonist treatment.
Based on these results, we used doses of GnRH that demonstrated high (1 ng) or moderate (100 pg) LH responses to determine if atrazine-treated animals would have an altered response after GnRH immunoneutralization. There were no significant differences between atrazine-treated groups and the control animals, suggesting that endocrine disruption by atrazine in the rodent is due to effects at the hypothalamus or higher brain regions and not the pituitary.
Atrazine and its metabolites are lipid soluble and should cross the blood-brain barrier to directly affect GnRH neurons or upstream modulators [40] . Cooper et al. [41] demonstrated that the concentration of the GnRH decapeptide is increased in the median eminence of the atrazine-treated rat. This suggests that atrazine works at the level of the hypothalamus to inhibit GnRH release. While it is known that GnRH neurons are spontaneously oscillatory, it is unknown how this scattered group of neurons is entrained to produce a synchronized release of GnRH. It remains unclear whether atrazine acts directly on GnRH neurons or on one of many neurotransmitter-containing neurons in the brain that are known to be involved in GnRH release [42, 43] .
Several neurotransmitters and neuropeptides involved in GnRH release have been reported to be altered by atrazine. Atrazine inhibits the binding of Ro15-4513 (a gamma aminobutyric acid receptor antagonist) to cortical membranes [44] . In male and female rats, atrazine altered catecholamine content in the hypothalamus. Atrazine treatment has been shown to decrease the concentrations of norepinephrine in the anterior and medial basal hypothalamus but to increase dopamine and its metabolite dihydroxy-phenyl acetic acid in the medial basal hypothalamus [45] [46] [47] . High doses of atrazine administered i.p. have led to hyperactivity and neurotoxicity in dopaminergic systems [48, 49] . While studies [4, [50] [51] [52] [53] have shown that atrazine can bind to the estrogen receptor, the affinity is at an insufficient level to affect physiology. Therefore, it is likely that atrazine does not target a specific neuronal population but rather changes central nervous system function in a nonspecific manner, thereby altering hypothalamic control of neuroendocrine activity. While atrazine, chlorotriazines, and chlorotriazine metabolites are found in the soil, ground and drinking water, and foodstuffs [54] , the concentrations of these compounds are in the range of parts per billion. This would imply that the levels of atrazine in humans and wildlife species are well below the concentrations used in the present study.
In conclusion, although LH pulse period and amplitude were increased in atrazine-treated animals, the anterior pituitary function does not seem to be altered by atrazine, as LH levels were not reduced in atrazine-treated animals in response to a GnRH agonist after GnRH immunoneutralization. Therefore, the inhibition of LH pulses and the disruption of cyclicity in female rats treated with atrazine are likely to be mediated by interference with central mechanisms controlling GnRH release from the hypothalamus. Although the doses of atrazine used in this study are high, the data support the hypothesis that the brain is the primary target mediating the effect of atrazine on LH release in the rat.
